Jennifer Graves is a Neurology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8001 Frost St
San Diego, CA 92123
Telephone
858-966-5819Registry record last updated 18 Jul 2018.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year202514 payments$52,541openpaymentsdata.cms.gov ↗
- Novartis Pharmaceuticals CorporationProgram year20258 payments
- Amgen Inc.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
43.5%CD20-directed Cytolytic Antibody13.7%Kesimpta Pen100%Part D<11 patientsOther immunostimulants10.5%Copaxone100%Part D<11 patients+ 2 more classes in this area
Nervous system
43.5%Potassium Channel Blocker33.9%Dalfampridine Er100%Part D<11 patientsGabapentinoids9.7%Gabapentin100%Part D<11 patientsMusculoskeletal
12.9%gamma-Aminobutyric Acid-ergic Agonist12.9%Baclofen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2025–2026 per NIH RePORTER. The latest:
- Characterizing neurocognitive deficits in post-acute sequelae of COVID-19
Advanced Brain Monitoring, Inc.
FY2026$365,227R43AG094486 - Characterizing neurocognitive deficits in post-acute sequelae of COVID-19
Advanced Brain Monitoring, Inc.
FY2025$325,672R43AG094486
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”